SPECTROPHOTOMETRIC DETERMINATION OF THE MOLAR ACTIVITY OF A RADIOPHARMACEUTICAL BASED ON PHOSPHORUS-32 RADIONUCLIDE
In this study, a simple and sensitive spectrophotometric method was developed to determine the molar activity (Ci/mmol) of a
carrier-free phosphorus-32 labeled orthophosphoric acid radiopharmaceutical (H₃[³²P]PO₄). The method relies on the formation of
a yellow phospho– vanadium–molybdenum complex in nitric acid medium, showing a maximum absorbance at 410 nm. The
calibration equation was d = 0.07812·n + 0.00783 (n ×10 ⁸ mol), with R² = 0.9993. The⁻ limit of detection (LOD) was 0.17 µg and
the limit of quantification (LOQ) was 0.56 µg, with a linear working range of 0.31–4.96 µg of phosphorus. For the tested sample,
the molar activity was 8410 Ci/mmol and the deviation from the theoretical value was 1.06%.
1. Tennvall J, Brans B. EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases. Eur J Nucl Med
Mol Imaging. 2007; 34: 1324.
2. Volkert WA, Hoffman TJ. Therapeutic radiopharmaceuticals. Chem Rev 1999;99:2269.
3. Hosain F, Spencer RP. Radiopharmaceuticals for palliation of metastatic osseous lesions: Biologic and physical background.
Semin Nucl Med 1992;22:11.
4. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46:38S.
5. Das T, Pillai MRA. Options to meet the future global demand of radioisotopes for radionucldie therapy. Nucl Med Biol
2013;40:23.
6. Banerjee S, Das T, Chakraborty S, Venkatesh M. Emergence and present status of Lu-177 in targeted radiotherapy: The
Indian scenario. Radiochim Acta 2012;100:115.
7. Cheng Y., Kiess A.P., Herman J.M., Pomper M.G., Meltzer S.J., Abraham J.M. Phosphorus-32,a Clinically Available Drug,
Inhibits Cancer Growth by Inducing DNA Double-Strand Breakage. PLOS ONE // 2015; 1-11.
8. G.V.S. Ashok Kumar, J. Vithya, R. Kumar, C. R. Venkata Subramani. Development of a flowsheet for the radiochemical
processing of irradiated sulphate targets for the production of carrier-free 32P. Journal of Radioanalytical and Nuclear
Chemistry. 2014; 302:939-945.
9. Silva M, Luck JV, Siegel ME (2001) 32P chromic phosphate radiosynovectomy for chronic haemophilic synovitis.
Haemophilia 7(2):40–49
10. Prabhakar G, Sachdev SS, Umamaheswari S, Sivaprasad N, Bhatia MH, Chaudhari PR, Solav SV (2007) Development of
samarium [32P] phosphate colloid for radiosynoviorthesis applications: preparation, biological and preliminary clinical
studies experience. Appl Radiat Isot 65(12):1309– 1313
11. Pandey U, Saxena SK, Sarma HD, Tandon P, Ram R, Samuel G, Dash A, Venkatesh M (2008) Bioevaluation studies of 32P
incorporated mould brachytherapy sources for potential application in treatment of superficial tumors. Nucl Med Commun
29:717–723
12. Vivante H, Salgueiro M.J, Ughetti R, Nicolini J, Zubillaga M (2007) 32P-patch contact brachyradiotherapy in the
management of recalcitrant keloids and hypertrophic scars. Indian J Dermatol Venereol Leprol 73:336–339
Copyright (c) 2026 «ACTA NUUz»

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


.jpg)

1.png)






